These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 35124261)

  • 1. Neutralizing antibody activity against the B.1.617.2 (delta) variant 8 months after two-dose vaccination with BNT162b2 in health care workers.
    Benning L; Morath C; Bartenschlager M; Reineke M; Töllner M; Nusshag C; Kälble F; Reichel P; Schaier M; Klein K; Schnitzler P; Zeier M; Süsal C; Bartenschlager R; Speer C
    Clin Microbiol Infect; 2022 Jul; 28(7):1024.e7-1024.e12. PubMed ID: 35124261
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neutralizing Antibody Activity Against the B.1.617.2 (delta) Variant Before and After a Third BNT162b2 Vaccine Dose in Hemodialysis Patients.
    Benning L; Klein K; Morath C; Bartenschlager M; Kim H; Buylaert M; Reineke M; Töllner M; Nusshag C; Kälble F; Reichel P; Schnitzler P; Zeier M; Süsal C; Bartenschlager R; Schaier M; Speer C
    Front Immunol; 2022; 13():840136. PubMed ID: 35309320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Age-Dependent Reduction in Neutralization against Alpha and Beta Variants of BNT162b2 SARS-CoV-2 Vaccine-Induced Immunity.
    Kawasuji H; Morinaga Y; Tani H; Saga Y; Kaneda M; Murai Y; Ueno A; Miyajima Y; Fukui Y; Nagaoka K; Ono C; Matsuura Y; Niimi H; Yamamoto Y
    Microbiol Spectr; 2021 Dec; 9(3):e0056121. PubMed ID: 34851162
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Durability of Immune Response After COVID-19 Booster Vaccination and Association With COVID-19 Omicron Infection.
    Gilboa M; Regev-Yochay G; Mandelboim M; Indenbaum V; Asraf K; Fluss R; Amit S; Mendelson E; Doolman R; Afek A; Freedman LS; Kreiss Y; Lustig Y
    JAMA Netw Open; 2022 Sep; 5(9):e2231778. PubMed ID: 36107426
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IgG Anti-Spike Antibodies and Surrogate Neutralizing Antibody Levels Decline Faster 3 to 10 Months After BNT162b2 Vaccination Than After SARS-CoV-2 Infection in Healthcare Workers.
    Decru B; Van Elslande J; Steels S; Van Pottelbergh G; Godderis L; Van Holm B; Bossuyt X; Van Weyenbergh J; Maes P; Vermeersch P
    Front Immunol; 2022; 13():909910. PubMed ID: 35784321
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccine-Induced Antibody Responses against SARS-CoV-2 Variants-Of-Concern Six Months after the BNT162b2 COVID-19 mRNA Vaccination.
    Jalkanen P; Kolehmainen P; Haveri A; Huttunen M; Laine L; Österlund P; Tähtinen PA; Ivaska L; Maljanen S; Reinholm A; Belik M; Smura T; Häkkinen HK; Ortamo E; Kantele A; Julkunen I; Lempainen J; Kakkola L
    Microbiol Spectr; 2022 Apr; 10(2):e0225221. PubMed ID: 35262410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Healthcare Workers in South Korea Maintain a SARS-CoV-2 Antibody Response Six Months After Receiving a Second Dose of the BNT162b2 mRNA Vaccine.
    Choi JH; Kim YR; Heo ST; Oh H; Kim M; Lee HR; Yoo JR
    Front Immunol; 2022; 13():827306. PubMed ID: 35173736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation between anti-S IgG and neutralizing antibody titers against three live SARS-CoV-2 variants in BNT162b2 vaccine recipients.
    Higashimoto Y; Kozawa K; Miura H; Kawamura Y; Ihira M; Hiramatsu H; Suzuki R; Haga K; Takai-Todaka R; Sawada A; Katayama K; Yoshikawa T
    Hum Vaccin Immunother; 2022 Nov; 18(6):2105611. PubMed ID: 36094467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kinetics of Neutralizing Antibodies against Omicron Variant in Vietnamese Healthcare Workers after Primary Immunization with ChAdOx1-S and Booster Immunization with BNT162b2.
    Chau NVV; Nguyet LA; Dung NT; Quang VM; Truong NT; Toan LM; Hung LM; Man DNH; Khoa DB; Phong NT; Ngoc NM; Thao HP; Ty DTB; Thanh PB; Ny NTH; Thanh LK; Thuy CT; Anh NT; Hong NTT; Nhu LNT; Yen LM; Thwaites G; Thanh TT; Tan LV;
    Am J Trop Med Hyg; 2023 Jan; 108(1):137-144. PubMed ID: 36450229
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neutralizing antibody response against the B.1.617.2 (delta) and the B.1.1.529 (omicron) variants after a third mRNA SARS-CoV-2 vaccine dose in kidney transplant recipients.
    Benning L; Morath C; Bartenschlager M; Kim H; Reineke M; Beimler J; Buylaert M; Nusshag C; Kälble F; Reichel P; Töllner M; Schaier M; Klein K; Benes V; Rausch T; Rieger S; Stich M; Tönshoff B; Weidner N; Schnitzler P; Zeier M; Süsal C; Hien Tran T; Bartenschlager R; Speer C
    Am J Transplant; 2022 Jul; 22(7):1873-1883. PubMed ID: 35384272
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Humoral immune response after different SARS-CoV-2 vaccination regimens.
    Rose R; Neumann F; Grobe O; Lorentz T; Fickenscher H; Krumbholz A
    BMC Med; 2022 Jan; 20(1):31. PubMed ID: 35057798
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early Humoral Responses of Hemodialysis Patients after COVID-19 Vaccination with BNT162b2.
    Speer C; Göth D; Benning L; Buylaert M; Schaier M; Grenz J; Nusshag C; Kälble F; Kreysing M; Reichel P; Töllner M; Hidmark A; Ponath G; Schnitzler P; Zeier M; Süsal C; Morath C; Klein K
    Clin J Am Soc Nephrol; 2021 Jul; 16(7):1073-1082. PubMed ID: 34031181
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High Incidence of SARS-CoV-2 Variant of Concern Breakthrough Infections Despite Residual Humoral and Cellular Immunity Induced by BNT162b2 Vaccination in Healthcare Workers: A Long-Term Follow-Up Study in Belgium.
    Calcoen B; Callewaert N; Vandenbulcke A; Kerstens W; Imbrechts M; Vercruysse T; Dallmeier K; Van Weyenbergh J; Maes P; Bossuyt X; Zapf D; Dieckmann K; Callebaut K; Thibaut HJ; Vanhoorelbeke K; De Meyer SF; Maes W; Geukens N
    Viruses; 2022 Jun; 14(6):. PubMed ID: 35746728
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants.
    Groß R; Zanoni M; Seidel A; Conzelmann C; Gilg A; Krnavek D; Erdemci-Evin S; Mayer B; Hoffmann M; Pöhlmann S; Liu W; Hahn BH; Beil A; Kroschel J; Jahrsdörfer B; Schrezenmeier H; Kirchhoff F; Münch J; Müller JA
    EBioMedicine; 2022 Jan; 75():103761. PubMed ID: 34929493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eleven-month longitudinal study of antibodies in SARS-CoV-2 exposed and naïve primary health care workers upon COVID-19 vaccination.
    Dobaño C; Ramírez-Morros A; Alonso S; Ruiz-Olalla G; Rubio R; Vidal M; Prados de la Torre E; Jairoce C; Mitchell RA; Barrios D; Jiménez A; Rodrigo Melero N; Carolis C; Izquierdo L; Zanoncello J; Aguilar R; Vidal-Alaball J; Moncunill G; Ruiz-Comellas A
    Immunology; 2022 Dec; 167(4):528-543. PubMed ID: 36065677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Humoral Response to BNT162b2 Vaccine Against SARS-CoV-2 Variants Decays After Six Months.
    Lopera TJ; Chvatal-Medina M; Flórez-Álvarez L; Zapata-Cardona MI; Taborda NA; Rugeles MT; Hernandez JC
    Front Immunol; 2022; 13():879036. PubMed ID: 35585980
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers.
    Lustig Y; Sapir E; Regev-Yochay G; Cohen C; Fluss R; Olmer L; Indenbaum V; Mandelboim M; Doolman R; Amit S; Mendelson E; Ziv A; Huppert A; Rubin C; Freedman L; Kreiss Y
    Lancet Respir Med; 2021 Sep; 9(9):999-1009. PubMed ID: 34224675
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mucosal immune response after the booster dose of the BNT162b2 COVID-19 vaccine.
    Azzi L; Dalla Gasperina D; Veronesi G; Shallak M; Maurino V; Baj A; Gianfagna F; Cavallo P; Dentali F; Tettamanti L; Maggi F; Maffioli LS; Tagliabue A; Accolla RS; Forlani G
    EBioMedicine; 2023 Feb; 88():104435. PubMed ID: 36628844
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of residual humoral immune response against SARS-CoV-2 by a surrogate virus neutralization test (sVNT) 9 months after BNT162b2 primary vaccination.
    Pezzati L; Milazzo L; Carrozzo G; Kullmann C; Oreni L; Beltrami M; Caronni S; Lai A; Caberlotto L; Ottomano C; Antinori S; Ridolfo AL
    J Infect Chemother; 2023 Jun; 29(6):624-627. PubMed ID: 36914095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro neutralizing activity of BNT162b2 mRNA-induced antibodies against full B.1.351 SARS-CoV-2 variant.
    Serrano-Conde E; Leyva A; Fuentes A; de Salazar A; Chueca N; Pérez-Castro S; Regueiro B; Rojas A; Mendoza J; Rojas J; García F
    Transbound Emerg Dis; 2022 Sep; 69(5):2649-2655. PubMed ID: 34910373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.